Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.

Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K

Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K.

Afiliação

Chen J; Global Product Development, Pfizer Oncology, New York, NY, USA. joseph.chen@pfizer.com.
Xu H; Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA.
Pawlak S; Global Product Development, Pfizer Inc., New Haven, CT, USA.
James LP; Global Product Development, Pfizer Oncology, New York, NY, USA.
Peltz G; Safety Surveillance and Risk Management, Pfizer Oncology, Groton, CT, USA.
Lee K; Global Product Development, Pfizer Inc., Groton, CT, USA.
Ginman K; Global Product Development, Pfizer Inc., South Lyon, MI, USA.
Bergeron M; Global Product Development, Pfizer Inc., Groton, CT, USA.
Pithavala YK; Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA.

Adv Ther ; 37(11): 4754, 2020 Nov.

Article em En | MEDLINE | ID: mdl-32910418

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article